↓ Skip to main content

An international consensus approach to the management of atypical hemolytic uremic syndrome in children

Overview of attention for article published in Pediatric Nephrology, April 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 2,232)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
28 tweeters
patent
2 patents
facebook
3 Facebook pages

Readers on

mendeley
179 Mendeley
Title
An international consensus approach to the management of atypical hemolytic uremic syndrome in children
Published in
Pediatric Nephrology, April 2015
DOI 10.1007/s00467-015-3076-8
Pubmed ID
Authors

Chantal Loirat, Fadi Fakhouri, Gema Ariceta, Nesrin Besbas, Martin Bitzan, Anna Bjerre, Rosanna Coppo, Francesco Emma, Sally Johnson, Diana Karpman, Daniel Landau, Craig B Langman, Anne-Laure Lapeyraque, Christoph Licht, Carla Nester, Carmine Pecoraro, Magdalena Riedl, Nicole C. A. J. van de Kar, Johan Van de Walle, Marina Vivarelli, Véronique Frémeaux-Bacchi

Abstract

Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g., using an anti-C5 antibody (eculizumab). We review treatment and patient management issues related to this therapeutic approach. We present consensus clinical practice recommendations generated by HUS International, an international expert group of clinicians and basic scientists with a focused interest in HUS. We aim to address the following questions of high relevance to daily clinical practice: Which complement investigations should be done and when? What is the importance of anti-factor H antibody detection? Who should be treated with eculizumab? Is plasma exchange therapy still needed? When should eculizumab therapy be initiated? How and when should complement blockade be monitored? Can the approved treatment schedule be modified? What approach should be taken to kidney and/or combined liver-kidney transplantation? How should we limit the risk of meningococcal infection under complement blockade therapy? A pressing question today regards the treatment duration. We discuss the need for prospective studies to establish evidence-based criteria for the continuation or cessation of anticomplement therapy in patients with and without identified complement mutations.

Twitter Demographics

The data shown below were collected from the profiles of 28 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 <1%
Denmark 1 <1%
Czechia 1 <1%
Germany 1 <1%
Unknown 175 98%

Demographic breakdown

Readers by professional status Count As %
Other 33 18%
Researcher 31 17%
Student > Master 24 13%
Student > Postgraduate 16 9%
Professor > Associate Professor 13 7%
Other 44 25%
Unknown 18 10%
Readers by discipline Count As %
Medicine and Dentistry 102 57%
Pharmacology, Toxicology and Pharmaceutical Science 8 4%
Agricultural and Biological Sciences 7 4%
Biochemistry, Genetics and Molecular Biology 6 3%
Nursing and Health Professions 5 3%
Other 18 10%
Unknown 33 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 39. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2019.
All research outputs
#479,356
of 14,131,697 outputs
Outputs from Pediatric Nephrology
#7
of 2,232 outputs
Outputs of similar age
#10,342
of 225,124 outputs
Outputs of similar age from Pediatric Nephrology
#1
of 52 outputs
Altmetric has tracked 14,131,697 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,232 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,124 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.